ProQR Therapeutics N.V. (NASDAQ: PRQR) Announce Seporfarse Study  in LCA10 Treatment...

0
ProQR Therapeutics N.V. (NASDAQ: PRQR) has revealed that its viral Phase 2/3 Illuminate study of sepofarsen for CEP290-Mediated Leber congenital amaurosis 10 (LCA10) treatment...

Reason why ReShape Lifesciences Stock (RSLS) is surging

0
ReShape Lifesciences Stock More than doubled and last traded at $17.04+10.74 (+170.48%). However, the stock lost quite a bit of steam after...

C3.ai Inc (NYSE:AI) gains over 30% in 3 days on strength...

0
ChatGPT has taken the world by storm and Buzzfeed (BZFD) got the party started with a ChatGPT PR last week which sent...

Popular News

MAKE IT MODERN

LATEST REVIEWS

Vaxart Inc. (NASDAQ:VXRT) Picks Its Lead Oral Coronavirus Vaccine Candidate And...

0
Vaxart Inc. (NASDAQ:VXRT) has announced that it has chosen its lead coronavirus vaccine candidate as well as contracted KindredBio to produce the vaccine in...

MAKE IT MODERN

PERFORMANCE TRAINING

Seelos Therapeutics Inc. (NASDAQ: SEEL) Announce License Agreement With iX Biopharma For Wafermine Commercialization

0
Seelos Therapeutics Inc. (NASDAQ: SEEL) and iX BioPharma have announced a license agreement pursuant to which iX Biopharma will license its lead drug candidate...

Sarepta Therapeutics Inc. (NASDAQ: SRPT) Reports Preliminary Q3 2021 Results And Data Analyse From...

0
Sarepta Therapeutics Inc. (NASDAQ: SRPT) has announced its preliminary Q3 2021 financial results. The company expects net product revenues of $166.9 million relative to...

CytomX Therapeutics Inc (NASDAQ: CTMX) Announces Phase 2 Findings For Praluzatamab Ravtansine in Breast...

0
CytomX Therapeutics Inc (NASDAQ: CTMX) has announced that its second phase study of praluzatamab rvtansine in individuals with hormone receptor-positive (HR+)/human epidermal growth factor...

Investing in Emerging Ad Tech Opportunities (PUBM, CRTO, CMGR, MGNI)

0
The Ad industry is rapidly evolving before our eyes. But evolution is nothing new to this space. It has always been in...

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Expects Full Year 2021 Revenue of $29.7 Million For...

0
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) has announced interim Q4 and full-year 2021 net revenue forecasts for its first in class oral XPO1 inhibitor, XPOVIO,...

MAKE IT MODERN

POPULAR

[/tdc_zone]